Big trial upside, cash still tight
- SELLAS is a pre-revenue biotech, so investor returns depend on trial wins and future funding.
- GPS passed the REGAL interim analysis in January 2025 and was at 72 of 80 final events in December 2025.
- SLS009 met all primary endpoints in Phase 2 r/r AML and showed median overall survival of 8.8 to 8.9 months in named cohorts.
- The company still carries a going concern warning and relies on dilutive stock sales to fund work.
- A binding arbitration with 3D Medicines over $13M plus in milestones is a key cash catalyst.
Two shots, one thin wallet
SELLAS is a high-risk biotech with real clinical shots. The lead drug, GPS, is in the Phase 3 REGAL study for acute myeloid leukemia, or AML. That trial passed its planned interim look in January 2025 and kept going without changes. By December 26, 2025, the trial had reached 72 deaths, close to the 80 needed for the final readout.
The second asset, SLS009, has become more important. In July 2025, SELLAS said SLS009 met all primary endpoints in a Phase 2 trial in relapsed or refractory AML. Median overall survival was 8.9 months in AML MR patients and 8.8 months in patients relapsed or refractory to venetoclax-based regimens at the 30 mg twice-weekly dose. The company compares that with a historical benchmark of about 2.4 months.
The bear case is simple: the science may be moving faster than the balance sheet. SELLAS has a going concern warning, no steady product sales, and depends on selling stock. If GPS misses its final survival goal, the company may not have enough runway to fund the wider SLS009 plan without heavy dilution.
The next watch items are clear. Investors are waiting for the REGAL final analysis at 80 events, the final ruling in the 3D Medicines arbitration, and first data from the new frontline AML Phase 2 study for SLS009.
Licenses in, raises cash, runs trials
SELLAS does not sell an approved drug today. It licenses or acquires cancer drug candidates, pays to move them through clinical trials, and hopes to create value through approval, partnerships, or future sales.
GPS was licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, a cancer-linked protein found in many tumors. SLS009 was licensed from GenFleet Therapeutics and is a selective CDK9 inhibitor, which means it is designed to block a cell-cycle related target that some cancer cells need.
The company can also make money by out-licensing regional rights. Its GPS deal with 3D Medicines covers Greater China. That deal is now a problem as well as a possible funding source, because SELLAS is in binding arbitration over milestone payments and development efforts.
Most funding still comes from public equity offerings and registered direct offerings. That keeps trials alive, but it can also shrink each existing shareholder's stake.
Pipeline bets to watch
GPS in AML maintenance
GPS is the lead program. Its Phase 3 REGAL study passed the January 2025 interim analysis and is waiting for the final analysis at 80 events.
SLS009 in relapsed or refractory AML
SLS009 met all primary endpoints in its Phase 2 r/r AML trial. SELLAS reported median overall survival of 8.8 to 8.9 months in specific cohorts.
SLS009 in frontline AML
After FDA guidance, SELLAS is advancing SLS009 into a randomized 80-patient Phase 2 study in first-line AML. This could widen the market if early results hold up.
SLS009 in lymphoma
SLS009 has also shown encouraging lymphoma data. In a Phase 2a combination study with zanubrutinib, SELLAS reported a 67% overall response rate.
GPS Greater China rights
SELLAS out-licensed GPS rights in Greater China to 3D Medicines. The value of this deal is clouded by the pending arbitration over milestones and development duties.
One reported business
SELLAS reports as one biopharmaceutical development segment. The split below shows that the filing view is one operating segment, with no separate revenue mix disclosed for products or regions.
What can break the story
REGAL final miss
High impact · Medium oddsGPS is the lead asset, and the REGAL trial is close to its final 80-event analysis. Passing the interim analysis lowered risk, but it did not prove final survival benefit. A failed final readout would hurt the main approval path and could make fundraising harder.
Cash runs short
High impact · High oddsSELLAS has a going concern warning and no steady product revenue. It funds work mainly through stock sales. More offerings could keep the company alive but dilute current investors.
3D Medicines ruling disappoints
Medium impact · Medium oddsSELLAS is seeking at least $13M in milestone-related claims from 3D Medicines. A hearing was held in January 2026, and the final determination is pending. A loss or delay would remove a possible source of non-dilutive cash.
SLS009 data does not repeat
High impact · Medium oddsThe Phase 2 SLS009 AML data look promising, but later studies may not match early cohort results. The frontline AML study is a bigger and more demanding test. Safety, survival, and response rates all need to stay strong.
Partner and rights limits
Medium impact · Medium oddsSELLAS does not own every right in every region. GPS Greater China rights are out-licensed to 3D Medicines, while SLS009 China rights remain with GenFleet. These limits can reduce future economics or slow global strategy.
In one breath
Does SELLAS have an approved drug?
No. SELLAS is still a clinical-stage company. Its value depends on trial results, regulatory decisions, partnerships, and its ability to raise money.
What is the biggest near-term catalyst for SLS stock?
The biggest clinical catalyst is the final Phase 3 REGAL readout for GPS at 80 events. The pending 3D Medicines arbitration decision is also important because it could affect cash.
Why does SLS009 matter if GPS is the lead drug?
SLS009 gives SELLAS a second major shot on goal. It met all primary endpoints in Phase 2 r/r AML and is moving into a first-line AML Phase 2 study after FDA guidance.
Why is SELLAS considered high risk?
The company has no steady product revenue, carries a going concern warning, and relies on dilutive financing. A bad GPS readout or a funding gap could sharply change the investment case.